AI Article Synopsis
- The emergence of immunotherapies, including CAR T-cell therapy, monoclonal antibodies, and vaccines, has significantly changed how various cancers are treated.* -
- A systematic review was conducted to explore the benefits and challenges of CAR T-cell therapy specifically for prostate cancer, resulting in 26 out of 183 records being deemed eligible.* -
- The review highlights the complexity of the tumor microenvironment in prostate cancer, which plays a crucial role in the effectiveness of immunotherapy treatments.*
Article Abstract
Recently, the development of immunotherapies such as cellular therapy, monoclonal antibodies, vaccines and immunomodulators has revolutionized the treatment of various cancer entities. In order to close the existing gaps in knowledge about cellular immunotherapy, specifically focusing on the chimeric antigen receptors (CAR) T-cells, their benefits and application in clinical settings, we conducted a comprehensive systematic review. Two co-authors independently searched the literature and characterized the results. Out of 183 records, 26 were considered eligible. This review provides an overview of the cellular immunotherapy landscape in treating prostate cancer, honing in on the challenges of employing CAR T-cell therapy. CAR T-cell therapy is a promising avenue for research due to the presence of an array of different tumor specific antigens. In prostate cancer, the complex microenvironment of the tumor vastly contributes to the success or failure of immunotherapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688882 | PMC |
| http://dx.doi.org/10.3390/cancers14225719 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!